COPD and Metabolic Syndrome: Unanswered Questions and Opportunities for Innovation.
作者信息
Krishnan Jamuna K, Bon Jessica
机构信息
Division of Pulmonary and Critical Care, Department of Medicine, Weill Cornell Medicine, New York, New York, United States.
Section of Pulmonary, Critical Care, Allergy, and Immunologic Diseases, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States.
出版信息
Chronic Obstr Pulm Dis. 2024 Nov 22;11(6):544-548. doi: 10.15326/jcopdf.2024.0576.
Abstract
摘要
相似文献
1
COPD and Metabolic Syndrome: Unanswered Questions and Opportunities for Innovation.慢性阻塞性肺疾病与代谢综合征：未解决的问题与创新机遇
Chronic Obstr Pulm Dis. 2024 Nov 22;11(6):544-548. doi: 10.15326/jcopdf.2024.0576.
2
Anxiety and depression in COPD: current understanding, unanswered questions, and research needs.慢性阻塞性肺疾病中的焦虑与抑郁：当前认识、未解决的问题及研究需求
Chest. 2008 Oct;134(4 Suppl):43S-56S. doi: 10.1378/chest.08-0342.
3
[Comorbidities of COPD].[慢性阻塞性肺疾病的合并症]
Rev Pneumol Clin. 2015 Dec;71(6):342-9. doi: 10.1016/j.pneumo.2015.09.009. Epub 2015 Nov 14.
4
Asthma-COPD Overlap Syndrome: Recent Insights and Unanswered Questions.哮喘-慢性阻塞性肺疾病重叠综合征：最新见解与未解决的问题
J Pers Med. 2022 Apr 28;12(5):708. doi: 10.3390/jpm12050708.
5
Prevalence and Correlates of Osteoporosis and Metabolic Syndrome Among Patients With Chronic Obstructive Pulmonary Disease at a Rural Tertiary Healthcare Center in India.印度一家农村三级医疗中心慢性阻塞性肺疾病患者中骨质疏松症和代谢综合征的患病率及相关因素
Cureus. 2025 Feb 9;17(2):e78759. doi: 10.7759/cureus.78759. eCollection 2025 Feb.
6
Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies.慢性阻塞性肺疾病（COPD）代谢综合征（MetS）的病理生物学机制：临床意义和治疗策略。
Pharmacol Ther. 2019 Jun;198:160-188. doi: 10.1016/j.pharmthera.2019.02.013. Epub 2019 Feb 26.
7
[Metabolic consequences of chronic obstructive pulmonary disease].[慢性阻塞性肺疾病的代谢后果]
Orv Hetil. 2021 Jan 31;162(5):185-191. doi: 10.1556/650.2021.31984.
8
Comorbidities of COPD in Bulgarian Patients - Prevalence and Association with Severity and Inflammation.保加利亚慢性阻塞性肺疾病患者的合并症——患病率及其与严重程度和炎症的关联
Folia Med (Plovdiv). 2018 Mar 1;60(1):102-109. doi: 10.1515/folmed-2017-0078.
9
Comorbidities in COPD: Current and Future Treatment Challenges.慢性阻塞性肺疾病的合并症：当前及未来的治疗挑战
J Clin Med. 2024 Jan 27;13(3):743. doi: 10.3390/jcm13030743.
10
Impact of comorbidities in COPD clinical control criteria. The CLAVE study.COPD 临床控制标准中合并症的影响。CLAVE 研究。
BMC Pulm Med. 2024 Jan 2;24(1):6. doi: 10.1186/s12890-023-02758-0.
引用本文的文献
1
Chronic Obstructive Pulmonary Disease and Metabolic Syndrome: A Maltese Study on Biomarkers and Clinical Implications.慢性阻塞性肺疾病与代谢综合征：一项关于生物标志物及临床意义的马耳他研究
Diabetes Metab Syndr Obes. 2025 Jul 21;18:2463-2476. doi: 10.2147/DMSO.S515061. eCollection 2025.
本文引用的文献
1
Lifestyle Intervention and Excess Weight in Chronic Obstructive Pulmonary Disease (COPD): INSIGHT COPD Randomized Clinical Trial.生活方式干预和慢性阻塞性肺疾病（COPD）中的超重问题：INSIGHT COPD 随机临床试验。
Ann Am Thorac Soc. 2023 Dec;20(12):1743-1751. doi: 10.1513/AnnalsATS.202305-458OC.
2
Incident low muscle mass is associated with greater lung disease and lower circulating leptin in a tobacco-exposed longitudinal cohort.在一个暴露于烟草的纵向队列中，事件性低肌肉质量与更严重的肺部疾病和循环瘦素水平降低相关。
Respir Res. 2023 Sep 22;24(1):224. doi: 10.1186/s12931-023-02521-3.
3
COPD and multimorbidity: recognising and addressing a syndemic occurrence.COPD 与多种共病：识别和应对综合征发生。
Lancet Respir Med. 2023 Nov;11(11):1020-1034. doi: 10.1016/S2213-2600(23)00261-8. Epub 2023 Sep 8.
4
Association of GLP-1 Receptor Agonists with Chronic Obstructive Pulmonary Disease Exacerbations among Patients with Type 2 Diabetes.GLP-1 受体激动剂与 2 型糖尿病患者慢性阻塞性肺疾病加重的相关性。
Am J Respir Crit Care Med. 2023 Nov 15;208(10):1088-1100. doi: 10.1164/rccm.202303-0491OC.
5
Disparities in Guideline Concordant Statin Treatment in Individuals With Chronic Obstructive Pulmonary Disease.慢性阻塞性肺疾病患者他汀类药物治疗指南依从性的差异
Chronic Obstr Pulm Dis. 2023 Oct 26;10(4):369-379. doi: 10.15326/jcopdf.2023.0395.
6
Race and Sex Differences in Mortality in Individuals with Chronic Obstructive Pulmonary Disease.慢性阻塞性肺疾病患者的死亡率存在种族和性别差异。
Ann Am Thorac Soc. 2022 Oct;19(10):1661-1668. doi: 10.1513/AnnalsATS.202112-1346OC.
7
Integrated disease management interventions for patients with chronic obstructive pulmonary disease.慢性阻塞性肺疾病患者的综合疾病管理干预措施。
Cochrane Database Syst Rev. 2021 Sep 8;9(9):CD009437. doi: 10.1002/14651858.CD009437.pub3.
8
Trends in the Prevalence of Metabolic Syndrome in the United States, 2011-2016.美国代谢综合征流行趋势，2011-2016 年。
JAMA. 2020 Jun 23;323(24):2526-2528. doi: 10.1001/jama.2020.4501.
9
Obesity and Severity of Acute Exacerbation of Chronic Obstructive Pulmonary Disease.肥胖与慢性阻塞性肺疾病急性加重严重程度的关系。
Ann Am Thorac Soc. 2018 Feb;15(2):184-191. doi: 10.1513/AnnalsATS.201706-485OC.
10
Impact of overweight and obesity on acute exacerbations of COPD - subgroup analysis of the Taiwan Obstructive Lung Disease cohort.超重和肥胖对慢性阻塞性肺疾病急性加重的影响——台湾阻塞性肺病队列的亚组分析
Int J Chron Obstruct Pulmon Dis. 2017 Sep 12;12:2723-2729. doi: 10.2147/COPD.S138571. eCollection 2017.
Zotero 插件